In our model of murine BMT, the lethal GVHD which develops against DBA/2 host incompatible minor histocompatibility antigens (mHAgs) can be prevented by donor preimmunization before grafting. Recipient mice become long survivors (LS mice) and tolerant to host mHAgs. However, a GVL effect is preserved and mediated by CD8
leukemia, GVL) effect associated with BMT. 2 Data obtained from clinical as well as experimental studies suggested that GVL can be at least partially separated from GVHD. 3 These experimental approaches used clonal analysis, 4 ,5 CD25 ϩ , 6 CD4 ϩ , CD8 ϩ , [7] [8] [9] or NK 10 specific cell depletion, different conditioning regimens, 11 IL-2 12,13 or anti-CD3 mAb 14 treatments and delayed infusion of donor lymphocytes. 15, 16 No clear conclusions can be drawn from the results which indicated the contribution of one or other cell subset or the same type of subset in both reactions depending on antigenic disparity and type of tumor. The T cell repertoire involved in GVHD developing across mHAg barriers is complex, although the V␤ utilization within CD4 ϩ and CD8 ϩ subpopulations and the number of potential mHAg targets are claimed to be limited. [17] [18] [19] [20] However, the restricted tissue expression of some mHAgs [21] [22] [23] [24] raises the possibility that some mHAgs present on leukemic cells are not expressed on cell targets for GVHD. Therefore, more investigations identifying effector T cells and antigens that drive GVHD and GVL are required to elaborate therapeutic strategies able to confer GVL without GVHD.
In the murine allogeneic BMT model we used in this work, an acute GVHD developed in lethally irradiated (DBA/2 × B10.D2)F1 grafted with bone marrow and spleen cells of B10.D2 mice. GVHD mortality can be prevented by treating the donor with DBA/2 spleen cells before transplantation. 25 Those F1 recipients became full chimeras, survived long term (long survivor, LS mice) and developed an in vivo tolerance of host mHAgs. 26 Immunological studies have revealed that the absence of acute GVHD is associated with the inhibition of early CD4V␤3 ϩ and CD4V␤6 ϩ T cell infiltration specific for mtv-7 and mtv-6 encoded superantigens. 27 However, CD8 ϩ T cells infiltrated GVHD organs with evidence of frequent V␤ subset overexpressions regardless of whether GVHD developed or not. 17 Two to three months after transplantation, CD4 ϩ spleen cells from LS mice lost their capacity to proliferate in response to DBA/2 mHAgs but CD8 ϩ spleen cells still had an in vitro cytotoxic potential for P815 tumor cells. 28 In addition, P815 cells injected i.v. into LS mice were rejected by CD8 ϩ T cells demonstrating that in this model a beneficial GVL effect is effective in the absence of acute GVHD. To explain why the presence of CD8 ϩ T cells cytotoxic in vitro did not induce acute lethal GVHD mortality but did eliminate tumor cells in vivo, we postulated that in LS mice the CD8 ϩ CTL repertoire recognizing DBA/2 mHAgs target of GVHD may be at least partially tolerized (anergy or deletion) but that the repertoire specific for tissue-restricted antigens expressed on P815 mastocytoma cells, responsible for the observed GVL effect, is functional. This hypothesis implies that target antigens, as the T cell repertoire, differ, at least partially, in GVHD and GVL effects. Two categories of antigens can be targets of CTL on P815 tumor cells: (1) mHAgs shared between different normal tissues that can be implicated as antigenic targets of the GVHD as well as the GVL effect, and (2) antigens present solely on P815 tumor cells and not on normal tissues that are more likely involved in the GVL effect: this second category of antigens includes tissue-restricted mHAgs and truly tumor-associated antigens.
In this report, we analyzed in LS mice and in B10.D2 donor mice as controls (1) the level of cytotoxic activity (CTL) against tissue-restricted mHAgs or mHAgs coexpressed by spleen and P815 mastocytoma cells, and (2) the TCR ␤ chain repertoire of CD8 ϩ T cells responding specifically to P815 cells. We found that the CTL repertoire directed to host mHAgs restricted to spleen cells and to mHAgs coexpressed by spleen and P815 cells is partially unresponsive in LS mice but that a potent CTL activity against tissue-specific antigens expressed on P815 mastocytoma cells can be generated in response to in vivo tumor cell injection. In addition, the ␤ chain repertoire of the CD8 ϩ T cells responding to P815 cells is mainly polyclonal in B10.D2 mice while clonal or oligoclonal expansion of CD8 ϩ cells expressing recurrent gene segments were found in LS mice indicating a restricted response to P815 cells.
Materials and methods

Mice
B10.D2 (H-
, Mtv-6 ϩ , Mtv-7 ϩ ) from Jackson Laboratories (Bar Harbor, ME, USA) were bred in our animal facilities under pathogen-free conditions.
GVHD induction and protection
Mice protected from GVHD (referred as to LS mice) were obtained by grafting lethally irradiated (9.5 Gy) F1(DBA/2 × B10.D2) recipient mice with 10 7 bone marrow cells and 8 × 10 6 spleen cells from B10.D2 donor mice previously immunized i.v. with 2 × 10 7 DBA/2 nonirradiated spleen cells.
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P815 tumor cells
P815 is a mastocytoma derived from DBA/2 mice. These cells express class I but not class II molecules and only very low amounts of Fas antigen. P815 cells metastase into the spleen and liver when injected i.v. into mice. Cr release was measured in a ␥.LKB counter. The specific percentage of lysis was calculated as: 100 × (experimental release − spontaneous release)/(maximal release − spontaneous release). Blocking experiments were performed by mixing the effector cells at a given E:T ratio, with different numbers of cold DBA/2 spleen cells or P815 cells before adding the chromium-labeled target for the 4-h incubation period. Percentage inhibition was calculated as: 100 × (percent lysis in the presence of cold targets / percent lysis without cold targets).
Generation of cytotoxic T lymphocyte (CTL)
Cytofluorometric analysis
Lymphocytes from the spleen were collected from normal B10.D2 mice and LS mice before and 14 days after P815 cell i.v. injection and stained with both PE-conjugated anti-CD4 and FITC-conjugated anti-CD8 mAbs as described previously.
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CD8
ϩ -specific subset purification
were incubated with 5 l of CD8-coated MACS magnetic microbeads (Miltenyi Biotec, Paris, France) for 20 min at 4°C. Bead-coated CD8 ϩ cells were separated on a magnet (MACS) and the degree of purity was checked by staining with conjugated anti-CD4 and anti-CD8 mAbs. 17 
RNA extraction and cDNA synthesis
Total RNA was extracted with RNABle (Eurobio, Les Ulis, France) according to the manufacturer's instructions. Single-strand cDNA was synthesized using the First Strand Synthesis kit (Pharmacia Biotech, Orsay, France) and then diluted in 30 l of water.
PCR amplification and direct sequencing
PCR was performed using the 3′ primer C␤ AAAAGGCTACCCTCGTGTGCTTG and the 5′ primers V␤1 CCCAGTCGTTTTATACCTGAATGC, V␤2 TCA-CTGATACGGAGCTGAGGCT, V␤4 GCCTCAAGT-CGCTTCCAACCT, V␤6 CTCTCACTGTGACATCTGC, V␤8.1 CATTCTGGAGTTGGCTTCCC, V␤8.2 GTCTGT-AGAGCCGGAGGA, V␤10 AGGGTCTGTAGAGCC-GGAGGAC, V␤12 GAAGATGGTGGGGCTTTTCCA-AGGATC, V␤15 CCCATCAGTCATCCCAACTTATCC. cDNA 1/30 was amplified by PCR with 12.5 pm of V␤-and C␤-specific oligonucleotides in the presence of 2.5 mm MgCl 2 , 10 mM dNTPs, 1.5 U Taq polymerase. The mixtures were submitted to 35 cycles, each consisting of 45 s at 94°C, 1 min at 60°C, and 1 min at 72°C. PCR products were purified using a Wizard DNA clean-up system (Promega, Charbonnières, France) and directly sequenced using the Thermo Sequenase radiolabeled terminator cycle sequencing kit (Amersham Life Science, Orsay, France), the same V␤ specific primers but a different internal C␤ primer: C␤2 CCAAGCACACGAGGGTAGCCTT.
Results
F1
(DBA/2 × B10.D2) mice grafted with preimmunized B10.D2 cells became fully chimeric and did not develop GVHD against DBA/2 host mHAgs (LS mice) but were still able to reject DBA/2 P815 tumor cells. To determine whether or not the repertoire of T cells recognizing antigens expressed on P815 tumor cells is distinct from that of T cells recognizing mHAgs expressed on normal spleen cells, we measured the cytotoxic capacity of splenic CD8 ϩ T cells generated following immunization of LS mice with DBA/2 splenic cells or with P815 tumor cells.
Cytotoxic activity generated following injection of DBA/2 spleen cells into LS and B10.D2 mice
CTL were induced by injecting i.v. 5 × 10 6 DBA/2 spleen cells into LS mice and into normal B10.D2 mice as controls and by restimulating spleen cells in vitro with irradiated DBA/2 spleen cells. The level of cytotoxicity against DBA/2 splenic blasts and P815 targets was compared and the results in Figure 1 represent a typical experiment. A strong cytotoxic response was observed in immunized B10.D2 mice when tested against DBA/2 splenic blasts or against P815 cells (53% and 45% respectively at an effector to target ratio of 50:1). By contrast, the CTL generated in LS mice after injection of DBA/2 spleen cells displayed a low level of cytotoxicity for DBA/2 splenic blasts and for P815 cells (16% and 3% respectively at an E:T ratio = 50:1). 
Cytotoxic activity generated following injection of P815 cells into B10.D2 and LS mice
Normal B10.D2 mice and LS mice were injected i.v. with 5 × 10 3 P815 tumor cells and percentages of CD4 ϩ and CD8 ϩ T cells as well as cytotoxic responses were measured in their spleens 14 days later. B10.D2 as well as LS mice exhibited a significant (P Ͻ 0.001, Student's t-test) proliferation of CD8 ϩ T cells whose percentage increased twoand three-fold, respectively (data not shown). This reflects a strong response to class I-restricted antigens expressed on P815 cells, ie to mHAgs coexpressed on spleen and P815 mastocytoma cells and/or to tissue-specific mHAgs and/or to tumor-associated antigens.
In P815-immunized B10.D2 mice, cytotoxic activity was detected for DBA/2 splenic blasts as well as for P815 cells (36% and 55.1% respectively at an E:T = 50:1; Figure 2 ). The injection of the same number of P815 cells into LS mice induced a low cytotoxic activity for DBA/2 splenic blasts (15.6%, Figure 2 ) but interestingly a consistent CTL activity (41.5%) against P815 targets.
Cold target inhibition experiments (Table 1) showed that the addition of cold P815 cells blocked the cytotoxic response against DBA/2 chromium-labeled targets of P815 immunized B10.D2 mice and LS mice as efficiently as cold DBA/2 spleen cells (66% and 74% inhibition by cold P815 cells in comparison with 87% and 83%, respectively, by cold DBA/2 spleen cells at a ratio of 20:1). Conversely, the CTL responses to chromium-labeled P815 targets were only slightly inhibited by the addition of cold DBA/2 spleen cells (19% for B10.D2 mice and 27% for LS mice at the same ratio) while the addition of the same number of cold P815 cells reduced the cytotoxic response much more (56% and 77%, respectively). Additional experiments, not shown here, indicated that the addition of cold DBA/2 bone marrow cells did not inhibit the cytotoxic response of LS mice for P815 cells, indicating that CTL raised after P815 injection are not mainly specific for mHAgs expressed on myeloid cells.
Cytotoxic activity of B10.D2 and LS mice for H-2 b incompatible cells
To ensure that the reduced CTL capacity for DBA/2 mHAgs observed in LS mice was not the result of a general defect in the CTL repertoire following bone marrow transplantation, we compared the cytotoxic activity of B10.D2 and LS mice for H-2 b incompatible EL4 cells. of LS mice is partially unresponsive to tissue-specific mHAgs expressed on spleen cells and to mHAgs coexpressed on spleen and P815 mastocytoma cells; (3) the CD8 ϩ repertoire directed against tissue-specific antigens expressed on P815 mastocytoma cells (mHAgs or tumorassociated antigens) is functional in LS mice; and (4) the CD8 repertoire directed against H-2 third-party antigens is normal in LS mice.
TCR ␤ chain repertoire in B10.D2 and in LS mice injected or not with P815 cells
To investigate whether the anti-P815 repertoire of LS mice differs from that of B10.D2 donor mice in terms of activated T cell phenotype, we characterized the TCR ␤ chain used by CD8 ϩ cells collected from the spleen of B10.D2 and LS mice challenged 14 days earlier with 5 × 10 3 P815 cells. RNA was extracted from 5 × 10 5 purified CD8 ϩ cells prepared from four P815-injected B10.D2 and 12 P815-injected LS mice and from two untreated B10.D2 and six untreated LS mice as controls. cDNA was synthesized by reverse transcription, amplified by PCR using V␤1, V␤2, V␤4, V␤6, V␤8.1, V␤8.2, V␤10, V␤12 and V␤15 primers and a C␤1 primer and the purified PCR products were directly sequenced. Table 2 summarizes the data for each family of the V␤ gene segment and two types of results were obtained: (1) an unreadable sequence corresponds to a population that contains a mix of several CD8 ϩ T cells expressing different J␤ associated with a given V␤ (polyclonal); (2) the possible identification of the J␤ corresponds to the predominant expansion of one or a few T cells expressing the same J␤ segment associated with a given V␤ segment.
As expected, the various V␤ PCR products obtained from T cells of untreated B10.D2 donor mice were polyclonal ( Table 2) . Injection of P815 cells into B10.D2 mice induced CD8 ϩ cell proliferation which was polyclonal for most V␤ families and clonal for V␤2 linked to J␤2.5 in a single case.
A similar observation was made for CD8 ϩ T cells purified from the six untreated LS mice tested 2-5 months after grafting except in three cases where the J␤ could be B10.D2 1 − P P P P P P P P P B10.D2 2 − P P P P P P P P P B10.D2 3 + P P P N T P P N T P P B10.D2 4 + P J ␤2.5 P P P P P P P B10.D2 5 + P P P P P P P B10.D2 6 + P P P P P P P LS 1 5 − P P P P P P LS 2 4 − P P P P P P J ␤1.6 LS 3 2 − P P P P P P P P LS 4 5 − P J ␤2.5 P P P P P P LS 5 3
RNA was extracted from two untreated B10.D2 and six untreated LS mice and from four P815-treated B10.D2 and 12 P815-treated LS mice and cDNA was synthesized. V␤.C␤1 PCR reactions were performed with V␤-specific primers and their products directly sequenced with the C␤2 primer. J␤ is presented when possibly identified. Unreadable sequences are marked as polyclonal (P).
identified associated with different V␤ segments: V␤1J␤1.1, V␤2J␤2.5 and V␤15J␤1.6. In contrast, the phenotypic repertoire of T cells responding to P815 stimulation was completely different in LS mice than in B10.D2 mice: whereas most of the V␤ families were polyclonal in B10.D2 mice, clonal or oligoclonal expansions of T cells were frequently observed in the V␤1, V␤2 and V␤15 families and only occasionally in other V␤ families ( Table 2) . The most striking finding is the presence in different mice of recurrent TCR rearrangements: V␤1J␤1.3 and V␤2J␤2.5 in four cases, V␤1J␤2.7 and V␤2J␤2.7 in two cases and V␤15J␤2.7 in three cases. It is interesting to note that a V␤2J␤2.5 rearrangement was found in untreated LS mice and in P815-immunized LS mice as well as in P815-immunized B10.D2 mice. These results indicate that the CD8 ϩ repertoire emerging in response to P815 cells is more restricted in LS mice than in B10.D2 donor mice. The amino acid composition of the junctional region of recurrent TCR rearrangements expressed by T cells activated in response to P815 cells is presented in Table 3 . The majority of the sequences for which the J␤ segment could be identified (16 of 19) were readable suggesting that the PCR products correspond to the amplification of one dominant clone. However, for one given V␤J␤ association, the junctional region differed between the mice in both length and amino acid composition, with no repeated sequences. Yet the V␤1J␤1.3 junctional region of LS4 and LS10 mice, as well as the V␤15J␤2.7 junctional region of LS2, LS7 and LS11 mice, are closely related. The deduced amino acid sequences of the V-D-J junction of clonal PCR products are presented in single letter amino acid codes from the end of the V␤ sequences to the start of the J␤ sequences. a PCR products were obtained from 12 P815-treated LS mice whose numbering corresponds to the mice reported in Table 2 .
Discussion
We sought to understand how, in our murine BMT model, CD8 ϩ T cells were able to display a GVL effect against P815 tumor growth without eliciting an acute GVHD. The CTL repertoire specific for DBA/2 mHAgs expressed on spleen cells overlapped the CTL repertoire specific for mHAgs expressed on P815 cells, but in LS mice (1) part of CTL directed against host splenic mHAgs was unresponsive, likely contributing to the absence of GVHD, and (2) CTL specific for mHAgs whose expression is restricted to mastocytoma cells and which are not present on normal spleen cells, were preferentially activated following in vivo injection of P815 cells.
Arguments supporting these conclusions were derived from the comparison of CTL activity of B10.D2 and LS mice injected with DBA/2 spleen cells or P815 cells. First, it is important to note that P815 target cells are susceptible to lysis through the perforin-mediated cytolytic pathway rather than through the Fas/Fas ligand cytolytic pathway. 29 In normal B10.D2 mice, immunization with DBA/2 spleen cells stimulated CTL specific not only for mHAgs expressed on spleen cells but also on P815 cells. Similarly, immunization with P815 cells generated T cells cytotoxic for both DBA/2 spleen and P815 cells demonstrating that these cells shared common antigenic epitopes. However, the level of cytotoxicity is always higher when immunizing cells and target cells are the same, due to the stimulation of an mHAgs tissue-specific T cell repertoire in addition to the shared repertoire.
CTL activity against the DBA/2 spleen target generated after DBA/2 spleen or P815 cell injection is always much weaker when T cells are derived from immunized LS mice rather than from immunized B10.D2 mice, while CTL activity against H-2 third-party antigens is similar in the two groups of mice. In contrast, CTL activity against P815 target could be generated in LS mice after P815 but not after DBA/2 spleen cell injection. In addition, this cytotoxic activity for P815 cells can only be marginally blocked by normal DBA/2 spleen cells. These results indicate that CTL recognizing host mHAgs, whose expression is restricted to the spleen or shared between spleen and P815 mastocytoma cells, were partially unresponsive in LS mice. Establishment of tolerance by exhaustion and/or induction of anergy following donor immunization and BMT could explain the functional disappearance of these host-reactive T cells potentially implicated in GVHD. 26 Furthermore, injection of P815 cells into LS mice generates predominantly CTL cells specific for antigens restricted to P815 mastocytoma cells, the repertoire of which was not tolerized, and only marginally CTL cells specific for mHAgs coexpressed on spleen and P815 cells.
The TCR used by the CD8 ϩ cells activated in response to P815 cells was characterized by direct sequencing of the individual V␤-C␤ PCR products in the V␤ families where clonal expansions were recurrently observed. This approach enabled us directly to obtain readable sequences from PCR products but limits the detection of T cells showing high frequency clonal V␤ expansions. Using this method, we demonstrated that the TCR repertoire of CD8 ϩ T cells activated by P815 cells, which is generally polyclonal in B10.D2 donor mice, exhibits in LS mice an overall reduction in the diversity of both V␤ and J␤ usage. Indeed, in P815-injected LS mice, clonal or oligoclonal expansions were very frequent in CD8 ϩ T cells expressing V␤1, V␤2 and V␤15 segments, and occasional in CD8 ϩ T cells expressing V␤8.1, V␤10 and V␤12 segments (Table 2) . A strong skewing of J␤ gene usage was observed for T cells expressing TCR V␤1J␤1.3, V␤2J␤2.5, V␤2J␤2.7 and V␤15J␤2.7, although junctional regions generally differ between each individual mouse. Yet, the junctional region of V␤15J␤2.7 gene rearrangements showed closely related length and amino acid sequences. The observed reduction in the level of CTL activity for DBA/2 splenic cells and in the diversity of TCR ␤ chain usage by LS mice when compared to B10.D2 donor mice suggests that only a part of the T cell repertoire directed to DBA/2 mHAgs participates in the anti-P815 response in LS mice, the unresponding part being eliminated or anergized.
Antigenic targets of T cells expressing recurrent TCR rearrangements cannot be formally identified. However, the fact that T cells expressing V␤2J␤2.5 and V␤2J␤2.7 rearrangements, detected in the spleen of LS mice and of B10.D2 mice after immunization with P815 cells, were also found in the liver of F1 mice early after transplantation 17 and later in the spleen of LS mice, allow us to postulate that they recognize mHAgs shared by normal DBA/2 tissues and P815 cells. Furthermore, we hypothesized that V␤1J␤1.3 and V␤15J␤2.7 T cells are specific for antigens expressed on P815 cells, ie for mHAgs with limited tissue distribution or for truly tumor-associated antigens. We favor the first possibility because we presume that the GVL effect is predominantly an allogeneic reaction, ie that T cell recognition of host-specific mHAgs contributes more to tumor cell rejection than T cell recognition of tumorassociated antigens expressed on P815 cells. This presumption is based first on published data showing that most of the T cell clones established from allogeneic transplanted leukemic patients are directed against mHAgs present on the leukemic cell and frequently on normal recipient PBL 4, 5, 30, 31 but not against the junction region of bcr/abl fusion protein specific for CML 4, 5, 32 or for the product of the t(8;16) translocation specific for AML. 33 This hypothesis is further supported by our previous observation (Ref. 26 and data not shown) that F1 mice reconstituted with T cell-depleted bone marrow (TCD BM), which are depleted in thymus T cells specific for host mHAgs but not for tumor-specific antigens, were unable to mount a CTL response to P815 cells sufficient to eradicate tumor growth in vivo. However, we cannot exclude that T cells expressing V␤1J␤1.3 are specific for tumor-associated antigens expressed on P815 cells, since the syngeneic T cell response of DBA/2 mice to immunodominant epitopes expressed by P815 cells 34 is dominated by the recurrent rearrangements V␤1J␤1.2 and V␤1J␤2.5. 35 The usage of J␤1.3 instead of J␤1.2 can be explained by the fact that in our model we dealt with an allogeneic response where T cells originated from B10.D2 mice as opposed to DBA/2 mice in the syngeneic model. All these observations indicated that the GVL response associated with allotransplantation in LS mice is dominated by the activation of a few CD8 ϩ cytotoxic clones express-ing recurrent rearrangements and directed mainly against mHAgs and/or tumor-associated antigens restricted to P815 mastocytoma, and marginally against common mHAgs present on normal tissue and potential targets of GVHD. Therapeutic strategies involving infusion of donor T cells selected for their alloreactivity for tumor cells are a promising way to separate GVL from GVHD. Recent evidence for mHAgs expressed on lymphocytic and myeloid leukemic cells, 30 for which cytotoxic clones were generated in vitro from donor bone marrow, 32, 33 shows that this approach is potentially usable as adjuvant immunotherapy in the treatment of leukemia after BMT.
